In this study, we demonstrate for the first time that CB can inhibit DDP resistance of A549 lung cancer cells both in vitro and in vivo through inhibiting the PI3K/AKT and MEK/ERK pathways. This evidence concerns the gene AKT1 and lung carcinoma.